A Phase 3 Randomized Placebo-Controlled Double-Blind Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with P53 Wild-Type Advanced or Recurrent Endometrial Carcinoma (GOG 3083)

Go Back to All Clinical Trials

A Phase 3 Randomized Placebo-Controlled Double-Blind Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with P53 Wild-Type Advanced or Recurrent Endometrial Carcinoma (GOG 3083)

Brief description of study

The purpose of this research study is to further evaluate the safety and effectiveness of selinexor for maintenance in patients with TP53 wild-type endometrial cancer.

Clinical Study Identifier: s22-01114

ClinicalTrials.gov Identifier: NCT05611931

Principal Investigator: Bhavana Pothuri.

Other Investigators: Christina Grace Wilson, Kent Chan, Michelle Diane Swanson Lightfoot, Emeline Mariam Aviki, Marina Stasenko, Edward A Jimenez, Fabia Brisard Pierrot, Eva Chalas-Westermann, Kelly A Levine, Olivia Richardson Khouri, Leslie R Boyd.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies